Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia

Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2008-01, Vol.177 (1), p.66-74
Hauptverfasser: Huang, Steven K, Wettlaufer, Scott H, Hogaboam, Cory M, Flaherty, Kevin R, Martinez, Fernando J, Myers, Jeffrey L, Colby, Thomas V, Travis, William D, Toews, Galen B, Peters-Golden, Marc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 74
container_issue 1
container_start_page 66
container_title American journal of respiratory and critical care medicine
container_volume 177
creator Huang, Steven K
Wettlaufer, Scott H
Hogaboam, Cory M
Flaherty, Kevin R
Martinez, Fernando J
Myers, Jeffrey L
Colby, Thomas V
Travis, William D
Toews, Galen B
Peters-Golden, Marc
description Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.
doi_str_mv 10.1164/rccm.200706-963OC
format Article
fullrecord <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2176116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17916807</sourcerecordid><originalsourceid>FETCH-LOGICAL-h285c-560be7942cbb08abd68029384e2c4b3edc953fe31293bd162bd86305097803de3</originalsourceid><addsrcrecordid>eNpVkUlLBDEQhYMo7j_Ai_RF8NKarZPORZDBDQQHccRbqKQz05F0tyQ9iv_eiON2StWrrx7FC0IHBJ8QIvhptLY7oRhLLEol2N1kDW2TilUlVxKv5xpLVnKunrbQTkrPGBNaE7yJtohURNRYbiP7CNGDCa6YxiGNsAjQN74vLmhx75LPSm9dkYVLb-JgAqQxFfM4dMUURu_63L35sS1maQmhuOlHF9PoR5-bae-W3dB72EMbcwjJ7a_eXTS7vHiYXJe3d1c3k_PbsqV1ZctKYOOk4tQag2swTb6QKlZzRy03zDVWVWzuGMmiaYigpqkFwxVWssascWwXnX35vixNl_F8XYSgX6LvIL7rAbz-P-l9qxfDq6ZEihxoNjj8a_Cz-R1XBo5WACQLYR5zOj79ckpVvMI8c8dfXOsX7ZuPTqcOQsi2RMPz57cRKTXRQrAPhbmLDQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</title><source>MEDLINE</source><source>American Thoracic Society (ATS) Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Huang, Steven K ; Wettlaufer, Scott H ; Hogaboam, Cory M ; Flaherty, Kevin R ; Martinez, Fernando J ; Myers, Jeffrey L ; Colby, Thomas V ; Travis, William D ; Toews, Galen B ; Peters-Golden, Marc</creator><creatorcontrib>Huang, Steven K ; Wettlaufer, Scott H ; Hogaboam, Cory M ; Flaherty, Kevin R ; Martinez, Fernando J ; Myers, Jeffrey L ; Colby, Thomas V ; Travis, William D ; Toews, Galen B ; Peters-Golden, Marc</creatorcontrib><description>Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/rccm.200706-963OC</identifier><identifier>PMID: 17916807</identifier><language>eng</language><publisher>New York, NY: Am Thoracic Soc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Cell Division - drug effects ; Cell Line ; Clinical death. Palliative care. Organ gift and preservation ; Collagen Type I - metabolism ; Cyclic AMP - metabolism ; Dinoprostone - pharmacology ; Drug Resistance ; E. Interstitial Lung Disease ; Female ; Fibroblasts - drug effects ; Fibroblasts - pathology ; Humans ; Intensive care medicine ; Lung - pathology ; Lung Diseases, Interstitial - pathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pulmonary Fibrosis - pathology</subject><ispartof>American journal of respiratory and critical care medicine, 2008-01, Vol.177 (1), p.66-74</ispartof><rights>2008 INIST-CNRS</rights><rights>Copyright © 2008, American Thoracic Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,4012,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19954504$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17916807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Steven K</creatorcontrib><creatorcontrib>Wettlaufer, Scott H</creatorcontrib><creatorcontrib>Hogaboam, Cory M</creatorcontrib><creatorcontrib>Flaherty, Kevin R</creatorcontrib><creatorcontrib>Martinez, Fernando J</creatorcontrib><creatorcontrib>Myers, Jeffrey L</creatorcontrib><creatorcontrib>Colby, Thomas V</creatorcontrib><creatorcontrib>Travis, William D</creatorcontrib><creatorcontrib>Toews, Galen B</creatorcontrib><creatorcontrib>Peters-Golden, Marc</creatorcontrib><title>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Division - drug effects</subject><subject>Cell Line</subject><subject>Clinical death. Palliative care. Organ gift and preservation</subject><subject>Collagen Type I - metabolism</subject><subject>Cyclic AMP - metabolism</subject><subject>Dinoprostone - pharmacology</subject><subject>Drug Resistance</subject><subject>E. Interstitial Lung Disease</subject><subject>Female</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - pathology</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Lung - pathology</subject><subject>Lung Diseases, Interstitial - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary Fibrosis - pathology</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUlLBDEQhYMo7j_Ai_RF8NKarZPORZDBDQQHccRbqKQz05F0tyQ9iv_eiON2StWrrx7FC0IHBJ8QIvhptLY7oRhLLEol2N1kDW2TilUlVxKv5xpLVnKunrbQTkrPGBNaE7yJtohURNRYbiP7CNGDCa6YxiGNsAjQN74vLmhx75LPSm9dkYVLb-JgAqQxFfM4dMUURu_63L35sS1maQmhuOlHF9PoR5-bae-W3dB72EMbcwjJ7a_eXTS7vHiYXJe3d1c3k_PbsqV1ZctKYOOk4tQag2swTb6QKlZzRy03zDVWVWzuGMmiaYigpqkFwxVWssascWwXnX35vixNl_F8XYSgX6LvIL7rAbz-P-l9qxfDq6ZEihxoNjj8a_Cz-R1XBo5WACQLYR5zOj79ckpVvMI8c8dfXOsX7ZuPTqcOQsi2RMPz57cRKTXRQrAPhbmLDQ</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Huang, Steven K</creator><creator>Wettlaufer, Scott H</creator><creator>Hogaboam, Cory M</creator><creator>Flaherty, Kevin R</creator><creator>Martinez, Fernando J</creator><creator>Myers, Jeffrey L</creator><creator>Colby, Thomas V</creator><creator>Travis, William D</creator><creator>Toews, Galen B</creator><creator>Peters-Golden, Marc</creator><general>Am Thoracic Soc</general><general>American Lung Association</general><general>American Thoracic Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20080101</creationdate><title>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</title><author>Huang, Steven K ; Wettlaufer, Scott H ; Hogaboam, Cory M ; Flaherty, Kevin R ; Martinez, Fernando J ; Myers, Jeffrey L ; Colby, Thomas V ; Travis, William D ; Toews, Galen B ; Peters-Golden, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h285c-560be7942cbb08abd68029384e2c4b3edc953fe31293bd162bd86305097803de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Division - drug effects</topic><topic>Cell Line</topic><topic>Clinical death. Palliative care. Organ gift and preservation</topic><topic>Collagen Type I - metabolism</topic><topic>Cyclic AMP - metabolism</topic><topic>Dinoprostone - pharmacology</topic><topic>Drug Resistance</topic><topic>E. Interstitial Lung Disease</topic><topic>Female</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - pathology</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Lung - pathology</topic><topic>Lung Diseases, Interstitial - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary Fibrosis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Steven K</creatorcontrib><creatorcontrib>Wettlaufer, Scott H</creatorcontrib><creatorcontrib>Hogaboam, Cory M</creatorcontrib><creatorcontrib>Flaherty, Kevin R</creatorcontrib><creatorcontrib>Martinez, Fernando J</creatorcontrib><creatorcontrib>Myers, Jeffrey L</creatorcontrib><creatorcontrib>Colby, Thomas V</creatorcontrib><creatorcontrib>Travis, William D</creatorcontrib><creatorcontrib>Toews, Galen B</creatorcontrib><creatorcontrib>Peters-Golden, Marc</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Steven K</au><au>Wettlaufer, Scott H</au><au>Hogaboam, Cory M</au><au>Flaherty, Kevin R</au><au>Martinez, Fernando J</au><au>Myers, Jeffrey L</au><au>Colby, Thomas V</au><au>Travis, William D</au><au>Toews, Galen B</au><au>Peters-Golden, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>177</volume><issue>1</issue><spage>66</spage><epage>74</epage><pages>66-74</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.</abstract><cop>New York, NY</cop><pub>Am Thoracic Soc</pub><pmid>17916807</pmid><doi>10.1164/rccm.200706-963OC</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2008-01, Vol.177 (1), p.66-74
issn 1073-449X
1535-4970
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2176116
source MEDLINE; American Thoracic Society (ATS) Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Adult
Aged
Aged, 80 and over
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Cell Division - drug effects
Cell Line
Clinical death. Palliative care. Organ gift and preservation
Collagen Type I - metabolism
Cyclic AMP - metabolism
Dinoprostone - pharmacology
Drug Resistance
E. Interstitial Lung Disease
Female
Fibroblasts - drug effects
Fibroblasts - pathology
Humans
Intensive care medicine
Lung - pathology
Lung Diseases, Interstitial - pathology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pulmonary Fibrosis - pathology
title Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A00%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Variable%20Prostaglandin%20E2%20Resistance%20in%20Fibroblasts%20from%20Patients%20with%20Usual%20Interstitial%20Pneumonia&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Huang,%20Steven%20K&rft.date=2008-01-01&rft.volume=177&rft.issue=1&rft.spage=66&rft.epage=74&rft.pages=66-74&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/rccm.200706-963OC&rft_dat=%3Cpubmed_pasca%3E17916807%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17916807&rfr_iscdi=true